MBL-1
MBL-1 is an orally active anti-inflammatory agent. MBL-1 can be isolated from the fermentation broth of Aspergillus sp. derived from gorgonians. MBL-1 inhibits the activity of the hCOX-2 protein with an IC50 of 5.77 μM. MBL-1 reduces the production of key pro-inflammatory mediators such as NO, ROS, IL-1β and IL-18 by inhibiting the MAPK/NF-κB and NLRP3 signaling pathways. MBL-1 exerts a protective effect against DSS-induced colitis. MBL-1 can be used for the research of ulcerative colitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1815632-13-3
- Formel: C25H26O7
- Molecular Weight:438.47
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
Fungal Metabolite |
hCOX-2 5.77 μM (IC50) |
NLRP3 |
IL-1β |
IL-18 |
In Vitro
MBL-1 potently inhibits the activity of hCOX-2 protein, with an IC50 value of 5.77 μM[1].
MBL-1 (0.5-50 μM; 24 h) shows no cytotoxicity in RAW 264.7, J774A.1 and MCF-7 cells even at the highest concentration of 50 μM[1].
MBL-1 (2-30 μM; 1 h) inhibits NO production in LPS-stimulated RAW 264.7 cells in a dose-dependent manner[1].
MBL-1 (2-30 μM; 1 h) dose-dependently inhibits LPS-induced ROS production in RAW 264.7 cells [1].
MBL-1 (2-30 μM; 1 h) inhibits the production of cytokines IL-6, IL-10 and IL-1β in LPS-stimulated RAW 264.7 cells in a dose-dependent manner[1].
MBL-1 (2-30 μM) dose-dependently inhibits LPS-induced phosphorylation of p38, ERK and JNK proteins in RAW 264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 J (male, 7 weeks old, DSS-induced colitis model)[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:p.o.; once daily; 7 days
-
Result:Mitigated DSS-induced body weight loss in a dose-dependent manner.
Attenuated progressive elevation of DAI scores in a dose-dependent manner.
Preserved colonic length in a dose-dependent manner, with 50 mg/kg dose resulting in a statistically significant increase compared to DSS-only controls.
Alleviated mucosal ulceration, preserved epithelial integrity, and reduced inflammatory cell infiltration; 50 mg/kg dose resulted in a statistically significant reduction in histological scores compared to DSS-only controls.
Chemical Information
-
CAS. Nr. 1815632-13-3
-
Molecular Weight 438.47
-
Formel C25H26O7
-
SMILES
COC([C@@]1(OC(C(OC)=C1C2=CC=C(C=C2)O)=O)CC3=CC(C/C=C(C)\C)=C(C=C3)O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
MBL-1 Related Classifications
HY-N6189 Related Classifications
Powered by Bioz